ADVERTISEMENT
China
Country
Rentschler Biopharma CEO Benedikt von Braunmühl tells In Vivo about the CDMO's strategic decision to exit the cell and gene therapy manufacturing space.
Indian CDMOs could consider collaborating with allies in Europe amid a focused effort via a new industry body to counter existing challenges like China’s manufacturing, regulatory and policy advantages and a shortage of funding and talent in the country even as talk of US tariffs throws a new spoke in the wheel
Starboard Value CEO Jeffrey C. Smith and former Bayer consumer health chief Erica Mann among three added to board at Kenvue, which increasing the number of seats temporarily from 11 to 14 until trimming it to 13 at its 2025 annual shareholders meeting on a date yet to be set.
China's medical equipment industry is growing rapidly, driven by limited domestic presence in high-cost segments and increasing adoption of local products in areas like monitoring equipment, defibrillators, and ventilators. International giants dominate the high-end market, but domestic companies such as Neusoft Medical Systems and Mindray Medical are making significant strides.
China's medical equipment industry is growing rapidly, driven by limited domestic presence in high-cost segments and increasing adoption of local products in areas like monitoring equipment, defibrillators, and ventilators. International giants dominate the high-end market, but domestic companies such as Neusoft Medical Systems and Mindray Medical are making significant strides.
The president says 4 March would mark the start of tariffs he initially intended to take effect on 1 February before allowing a delay for Mexico and Canada to implement border security to help curb illegal entry by immigrants and fentanyl smuggling.
Following on a slew of approvals in the past year, Henlius announced the first overseas approval of its Avastin biosimilar in Bolivia where it is partnered with the Brazilian firm Eurofarma.
Generics Bulletin reviews the latest regulatory developments across the world.
Nauman Shah, head of business development for J&J Innovation, sat down at the BIO CEO & Investor Conference to talk about his trip to China and the state of the biotech scene there.
The US market’s largest imaging manufacturer marked two years as an independent company with plans to invest in more M&A and PDx production capacity, but reported a modest 2025 revenues outlook.